Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Vernon

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 2005
Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosisMarc Weiner, Debra Benator, Charles A Peloquin, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2007
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacinMarc Weiner, William Burman, Chi-Cheng Luo, et al.
Plos Medicine|September 16, 2009
Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysisDick Menzies, Andrea Benedetti, Anita Paydar, et al.
American Journal of Respiratory and Critical Care Medicine|April 10, 2010
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in BotswanaZegabriel Tedla, Samba Nyirenda, Crandall Peeler, et al.
The Pediatric Infectious Disease Journal|December 10, 2021
Management of Pediatric Thoracic Empyema in the North Queensland Region of Australia and Impact of a Local Evidence-based Treatment GuidelineAnil Gautam, Gregory Wiseman, Robert Legg, et al.
American Journal of Respiratory and Critical Care Medicine|January 18, 2003
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentineMarc Weiner, William Burman, Andrew Vernon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 22, 2005
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosisMarc Weiner, Debra Benator, William Burman, et al.
American Journal of Respiratory and Critical Care Medicine|June 5, 2002
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatmentNaomi N Bock, Timothy R Sterling, Carol D Hamilton, et al.
MMWR. Morbidity and Mortality Weekly Report|June 29, 2018
Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis InfectionAndrey S Borisov, Sapna Bamrah Morris, Gibril J Njie, et al.
American Journal of Respiratory and Critical Care Medicine|August 20, 2005
Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosisWilliam Burman, Debra Benator, Andrew Vernon, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 2005
Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosisMarc Weiner, Debra Benator, Charles A Peloquin, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2007
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacinMarc Weiner, William Burman, Chi-Cheng Luo, et al.
Plos Medicine|September 16, 2009
Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysisDick Menzies, Andrea Benedetti, Anita Paydar, et al.
American Journal of Respiratory and Critical Care Medicine|April 10, 2010
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in BotswanaZegabriel Tedla, Samba Nyirenda, Crandall Peeler, et al.
The Pediatric Infectious Disease Journal|December 10, 2021
Management of Pediatric Thoracic Empyema in the North Queensland Region of Australia and Impact of a Local Evidence-based Treatment GuidelineAnil Gautam, Gregory Wiseman, Robert Legg, et al.
American Journal of Respiratory and Critical Care Medicine|January 18, 2003
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentineMarc Weiner, William Burman, Andrew Vernon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 22, 2005
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosisMarc Weiner, Debra Benator, William Burman, et al.
American Journal of Respiratory and Critical Care Medicine|June 5, 2002
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatmentNaomi N Bock, Timothy R Sterling, Carol D Hamilton, et al.
MMWR. Morbidity and Mortality Weekly Report|June 29, 2018
Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis InfectionAndrey S Borisov, Sapna Bamrah Morris, Gibril J Njie, et al.
American Journal of Respiratory and Critical Care Medicine|August 20, 2005
Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosisWilliam Burman, Debra Benator, Andrew Vernon, et al.
Pageof 6